Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
2008-04-22
2008-04-22
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
C424S178100, C424S179100, C530S391100, C530S391700
Reexamination Certificate
active
11173969
ABSTRACT:
The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy.
REFERENCES:
patent: 5208020 (1993-05-01), Chari et al.
patent: 5916561 (1999-06-01), Adolf et al.
patent: 6323334 (2001-11-01), Kingsbury et al.
patent: 2004/0126379 (2004-07-01), Adolf et al.
patent: 0 425 235 (1991-05-01), None
patent: WO 97 21104 (1997-06-01), None
patent: WO 98 22508 (1998-05-01), None
patent: WO 98 39034 (1998-09-01), None
patent: WO 01 00244 (2001-01-01), None
patent: WO 01/24763 (2001-04-01), None
Minuno et al Drug Delivery System vol. 11 p. 385 (1996).
Muzino et al, Drug Delivery Syst. vol. 11 No. 6 p. 385-391 (1996).
Fowers, K. et al: “Targeting of HPMA copolymer-drug conjugates to A2780/AD ovarian cancer cells using anti-P-glycoprotein antibodies or fragments”; Proc. 25th Int. Symp. Controlled Release Bioact. Mater, (1999), 527-528.
Wu, M. et al: “Potent deglycosylated ricin A chain immunotoxins specific killing of xenotropic murine retrovirus-Infected cells”;Chin. Med. J., (1994) 107(5):383-385.
Eliaz, R. E. et al: “Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells”; Cancer Res., (2001), 61(6):2592-2601.
Csanaky, G. et al: “Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias”; Leukemia (1997), 11(3):408-15.
Lesley, J. et al: “Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1”; Experimental Cell Research (1990), 187(2):224-33.
Guo, Y. et al: “Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody”, Cancer Research (1994), 54(6):1561-5.
Heider, K-H et al: “Splice Variants of the Cell Surface Glycoprotein CD44 Associated with Metastatic Tumour Cells are Expressed in Normal Tissues of Humans and Cynomolgus Monkeys”; European J. of Cancer (1995) 31A (13/14):2385-2391, Pergamon Press, Oxford, GB.
Heider, K-H et al: “Characterization of A High-Affinity Monoclonal Antibody Specific for CD44V6 as Candidate for Immunotherapy of Squamous Cell Carcinomas”; Cancer Immunology and Immunotherapy, (1996), 43:245-253.
Chari R V J et al: “Immunoconjugates containing novel maytansinoids: Pormising Anticancer Drugs”; Cancer Research, American Association for Cancer Research, (1992), 52(1):127-131, Baltimore MD, US.
Liu, C. et al: “The development of antibody delivery systems to target cancer with highly potent maytansinoids”; Expert Opin. Invest. Drugs (1997), 6(2):169-172.
Liu, C. et al: “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids” Proc. Natl. Acad. Sci. U.S.A., (1996), 93(16):8618-8623.
Verel I. et al: “Tumor Targeting Properties of Monoclonal Antibodies with Different Affinity for Target Antigen CD44V6 In Nude Mice Bearing Head-And-Neck Cancer Xenografts”; Int. J. Cancer (2002), 99:396-402.
Newton, D. et al: “Anti-tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo.” Int. J. of Oncology (1996), 8:1095-1104.
Liu, C. et al: “Cure of large human colon cancer xenografts by a C242-Maytansinoid conjugate.” Proceedings of the American Assoc. for Cancer Res. Annual; 1996, 37:466-467, abst. #3183.
Smith, S.: “Technology evaluation: c242-DM1, ImmunoGen Inc.,” Current Opinion in Molecular Therapeutics; 2001, 3(2):198-203.
Somasundaram, C. et al: “ Development of a bispecific F(ab')2 conjugate against the complement receptor cr3 of macrophages and a variant cd44 antigen of rat pancreatic adenenocarcinoma for redirecting macrophage-mediated tumor cytotoxity”; Cancer Immunology and Immunotherapy, 1996, 42(6):343-350.
Monneret C. et al: “Ciblage de molecules antitumorales par les anticorps monoclonaux.” Bulletin Du Cancer; 2000, 87(11)829-838.
Adolf Guenther
Heider Karl-Heinz
Patzelt Erik
Sproll Marlies
Boehringer Ingelheim International GmbH
Devlin Mary-Ellen M.
Huff Sheela J.
Morris Michael P.
LandOfFree
Cytotoxic CD44 antibody immunoconjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic CD44 antibody immunoconjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic CD44 antibody immunoconjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3926903